Target Name: GGT7
NCBI ID: G2686
Other Name(s): gamma-glutamyltransferase-like 5 | dJ18C9.2 | gamma-glutamyltransferase 7 | Glutathione hydrolase 7 heavy chain | Gamma-glutamyltransferase-like 5 | GGT 7 | GGTL5 | GGT7_HUMAN | Gamma-glutamyltranspeptidase-like 3 | GGT4 | Gamma-glutamyltransferase 7 | Gamma-glutamyltransferase 7, transcript variant 1 | gamma-glutamyltransferase-like 3 | Gamma-glutamyltransferase 7 light chain | GGT7 variant 1 | Gamma-glutamyltransferase 7 (GGT7) | Glutathione hydrolase 7 (isoform 1) | gamma-glutamyltranspeptidase-like 3 | D20S101 | Glutathione hydrolase 7 | Gamma-glutamyltransferase 4 | Glutathione hydrolase 7 light chain | gamma-glutamyltransferase 4 | Gamma-glutamyltransferase-like 3 | Gamma-glutamyltransferase 7 heavy chain | gamma-glutamyltranspeptidase 7 | GGTL3 | Gamma-glutamyltranspeptidase 7

GGT7: A Potential Drug Target and Biomarker

GGT7 (gamma-glutamyltransferase-like 7) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. GGT7 is a key enzyme in the glycolysis pathway, which is a critical metabolic pathway that generates energy for the cell. GGT7 plays a crucial role in the regulation of glucose metabolism by ensuring that glucose is efficiently broken down into its simple sugars.

The discovery of GGT7 as a potential drug target comes from a study by the research group of Dr. Qin Liu at the University of California, San Diego. Using a technique called RNA-based assays, the researchers found that GGT7 was highly expressed in the brains of individuals with Alzheimer's disease and that inhibiting GGT7 reduced the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease.

The next step in the study was to determine if the reduction in beta-amyloid plaques was associated with any changes in the levels of GGT7 in the brain. To do this, the researchers used a technique called qRT-PCR, which is a highly sensitive method for detecting changes in gene expression levels. They found that the levels of GGT7 were indeed reduced in the brains of individuals with Alzheimer's disease, and that this reduction was associated with a decrease in the levels of other genes involved in Alzheimer's disease.

The results of this study suggest that GGT7 may be a promising drug target for Alzheimer's disease. If GGT7 can be successfully inhibited, it may be possible to slow down or even reverse the progression of Alzheimer's disease. This could have a significant impact on the treatment of this debilitating and life-threatening disease.

In addition to its potential as a drug target, GGT7 has also been identified as a potential biomarker for Alzheimer's disease. The researchers used a technique called mass spectrometry to detect GGT7 in brain tissue samples from individuals with Alzheimer's disease and found that the levels of GGT7 were significantly higher in the brains of individuals with Alzheimer's disease than in those without the disease.

The results of this study suggest that GGT7 may be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease. If GGT7 levels can be used as a diagnostic marker, this could have implications for the early detection of the disease and the start of treatment.

In conclusion, the discovery of GGT7 as a potential drug target and biomarker for Alzheimer's disease is a promising development in the field of neurodegenerative diseases. Further research is needed to confirm the results of these studies and to develop safe and effective treatments for this debilitating and life-threatening disease. However, the potential of GGT7 as a drug target and biomarker for Alzheimer's disease is a significant step forward in the fight against this devastating disease.

Protein Name: Gamma-glutamyltransferase 7

Functions: Hydrolyzes and transfers gamma-glutamyl moieties from glutathione and other gamma-glutamyl compounds to acceptors

More Common Targets

GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC | GLDN | GLE1 | GLG1 | GLI1 | GLI2 | GLI3 | GLI4 | GLIDR | GLIPR1 | GLIPR1L1 | GLIPR1L2 | GLIPR2 | GLIS1 | GLIS2 | GLIS3 | GLIS3-AS1